UPDATE: New Jersey jury hits BD subsidiary Bard with $68m pelvic mesh verdict

April 13, 2018 By Brad Perriello Leave a Comment

Updated to include a $35 million punitive damages verdict released today.

Becton Dickinson & Co. (NYSE:BDX) subsidiary C.R. Bard was reportedly hit yesterday with a $33 million verdict in a product liability lawsuit brought over its Avaulta and Align pelvic mesh products.

A New Jersey jury in the Bergen County Superior Court awarded $23 million in compensatory damages to plaintiff Mary McGinnis and $10 million to her husband, Thomas McGinnis, Courtroom View Network reported.

Bard was also hit with $35 million in punitive damages today, according to the CVN report.

The jury found that the Avaulta and Align meshes implanted to treat McGinnis’s bladder prolapse and stress urinary incontinence were defectively designed and left her in chronic pain, CVN reported. Bard argued that it tested Avaulta extensively and that McGinnis had other medical issues that caused her injuries. By 2016 the company had removed both products from the market, according to CVN.

Back in 2012 Bard lost a $5.5 million Avaulta verdict in California state court and another $2 million Avaulta case West Virginia the next year; in February 2016 Bard and co-defendant Boston Scientific (NYSE:BSX) won out in another suit brought over their respective Align and Solyx mesh devices.

BD closed its $24 billion acquisition of Bard late last year.

Inside Hologic's evolving definition of women's healthcare

Steve MacMillan took over as CEO of Hologic in 2013, drawing on his experience at medtech titans like Stryker and Johnson & Johnson. Since then, Hologic has grown into a $3 billion business.

At DeviceTalks Boston, MacMillan will provide exclusive insights into the Massachusetts-based company and its evolving definition of women's healthcare. You don't want to miss it!

REGISTER NOW

Use code WOMENSHEALTH to save an additional 10%.

Medtech should think deeper about the problems its trying to solve
Medtech can improve by thinking more about the problems it is trying to solve and looking outside of normal avenues for inspiration. Jeff Karp, Brigham and Women’s Hospital, Harvard Medical School. For companies and academics aiming to innovate in the medical space, we often don’t spend enough time thinking about the problem we are trying… […]
5 tips for post-market medical device compliance
Post-market surveillance is an important process for medical device developers and an expectation of regulatory bodies that you follow through and have effective procedures. Jon Speer, Greenlight Guru In fact, post-market surveillance is a compliance issue that many companies get caught up with in audits or inspections. So how comfortable is your medtech company with the… […]
11 pediatric cardiovascular devices you need to know
A bandage-sized heart monitor, an extracorporeal blood pump that mimics the human heart, and a heart valve that can grow with a child were among the six winners of a contest yesterday in Philadelphia for innovative pediatric cardiovascular devices. The Pediatric Device Innovation Symposium organized by the Sheikh Zayed Institute for Pediatric Surgical Innovation at… […]
Meddux Development receives ISO 13485:2016 certification
Meddux Development announced that it has received ISO 13485:2016 certification for its quality management system. “The certification to ISO 13485:2016 allows Meddux to offer its customers a streamlined path from concept to first-in-human clinical trials, David Schechter, president of Meddux, said. “Meddux has developed a flexible and responsive QMS capable of handling the most critical… […]
6 questions to ask when designing polymer components for medical devices
Choosing the right polymer for the job can be a daunting task. Here are the right questions to ask before you begin the process. Karen Heroldt, PolyOne Distribution Choosing polymers is complicated in the high-stakes world of medical and healthcare devices. Materials can have varied tool design, molding and secondary processing requirements that can affect… […]
Medtech M&A remains hot: Here’s how
M&A in medtech show no signs of slowing in the fourth quarter of 2018, and companies looking to buy or sell have much to consider, according to patent attorney David Dykeman, a shareholder in the Boston office of the global law firm Greenberg Traurig. The number of medtech M&A deals soared by 50% in 2017 and… […]
Olympus touts line of needles for GI disease improvement
Olympus is touting its new EZ Shot 3 Plus 25 G needles that is designed to help improve the staging of GI disease. The 25 G needle is an addition to the EZ Shot 3 Plus 19 G and 22 G needles that Olympus already markets. Olympus’s new EZ Shot 3 Plus 25 G needles… […]
Mindray North America picks Eastman medical polymers for patient monitors
Mindray is using Eastman’s medical polymers in its present generation of patient monitors in order to improve chemical resistance to cleaning/disinfection agents and increase device longevity, the companies recently announced. Thanks to the Eastman polymers, Mindray’s Passport series of bedside monitors, T1 monitor/module and Accutorr series of spot check monitors are now fully compatible with more than… […]
Cincinnati Children’s researchers report progress growing a human esophagus in a lab
It’s possible to use pluripotent stem cells to grow human esophageal organoids — another step toward the goal of someday bioengineering the entire esophagus and human gastrointestinal system in a lab, according to researchers at Cincinnati Children’s Center for Stem Cell and Organoid Medicine (CuSTOM). The Cincinnati Children’s researchers describe the advance as a first. Pluripotent stem… […]
How strong patent portfolios attract strategic investments and deals
Amassing strong patent portfolios helps medical device companies attract interest from strategic investors and potential acquirers. David J. Dykeman, Greenberg Traurig and Patrick West, Mirus Capital Advisors The medical device industry has demonstrated strong and sustainable growth in recent years. Given the aging population, increasing incidence of chronic and lifestyle diseases, emergence of artificial intelligence (AI)… […]
NucleusHealth wins investment from large Ohio health system
Cloud-based medical image exchange company NucleusHealth has landed an undisclosed “strategic investment” from Mercy Health, an Ohio–based health care system that is now a minority investor in the San Diego, Calif.-based company. NucleusHealth will use the money to help deliver Nucleus.io, the first cloud-based Picture Archiving Communications System (PACS) platform designed to use the security, scalability and… […]